But there are only 100 doses available. With limited supply, health officials plan to give doses of the vaccine to immediate contacts of confirmed Ebola cases. Scientists then hope to use these contacts as potential candidates in the vaccine’s clinical trial—though the exact testing protocol they will use is still being worked out.
Kaleebu says they are hoping for accelerated production from the Sabin Vaccine Institute now that more doses are needed. But even if the number of vaccines used in the trial is small, they will still provide useful data, says Bruce Kirenga, a senior respiratory physician at Makerere University College of Health Sciences on the outskirts of Kampala.
“Trials
→ Continue reading at Wired - Science